Literature DB >> 666973

Heparin pharmacokinetics: increased requirements in pulmonary embolism.

T L Simon, T M Hyers, J P Gaston, L A Harker.   

Abstract

Heparin disappearance after injection and plasma levels during continuous infusion were studied in normal subjects and patients with thrombophlebitis, pulmonary embolism, renal failure, and liver failure. Heparin removal in normal subjects after 75 u/kg was nearly linear with a clearance of 0.64 ml/min/kg, SD +/- 0.11. Clearance varied inversely with dose. Heparin clearance in pulmonary embolism (0.80 ml/min/kg +/- 0.23) was significantly accelerated compared both to normals (P less than 0.005) and to thrombophlebitis patients (0.55 ml/min/kg +/- 0.19, P less than 0.01); the disappearance was more curvilinear in thrombophlebitis and pulmonary embolism than in normal subjects (P less than 0.025). Continuous infusion heparin requirements were greater in pulmonary embolism than in thrombophlebitis, in accordance with pharmacokinetic predictions. The pattern and rate of disappearance in renal disease was similar to normal subjects; in liver disease clearance was accelerated (0.86 ml/min/kg +/- 0.28) and disappearance curvilinear. Because of accelerated clearance, the initial dose of heparin in pulmonary embolism should be greater (25 u/kg/h) than in thrombophlebitis (10-15 u/kg/h). Variability within patient groups necessitates some laboratory control of dosage.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 666973     DOI: 10.1111/j.1365-2141.1978.tb07133.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  11 in total

1.  Factors influencing platelet consumption by polyacrylamide hydrogels.

Authors:  S R Hanson; L A Harker; B D Ratner; A S Hoffman
Journal:  Ann Biomed Eng       Date:  1979       Impact factor: 3.934

Review 2.  Pharmacokinetic optimisation of the treatment of deep vein thrombosis.

Authors:  A Iorio; G Agnelli
Journal:  Clin Pharmacokinet       Date:  1997-02       Impact factor: 6.447

3.  Experimental arterial thromboembolism in baboons. Mechanism, quantitation, and pharmacologic prevention.

Authors:  L A Harker; S R Hanson
Journal:  J Clin Invest       Date:  1979-08       Impact factor: 14.808

4.  New method to predict patients' intravenous heparin dose requirements.

Authors:  B M Reilly; R A Raschke
Journal:  J Gen Intern Med       Date:  1996-03       Impact factor: 5.128

Review 5.  Pharmacokinetic optimisation of the treatment of embolic disorders.

Authors:  D M Lutomski; M Bottorff; K Sangha
Journal:  Clin Pharmacokinet       Date:  1995-01       Impact factor: 6.447

Review 6.  Heparin therapy. Regimens and treatment considerations.

Authors:  T M Hyers
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

7.  Plasma concentrations of endogenous heparinoids in portal hypertension.

Authors:  R F McKee; S Hodson; J Dawes; O J Garden; D C Carter
Journal:  Gut       Date:  1992-11       Impact factor: 23.059

Review 8.  Heparin pharmacokinetics and pharmacodynamics.

Authors:  R J Kandrotas
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

Review 9.  Clinical pharmacokinetics of heparin.

Authors:  J W Estes
Journal:  Clin Pharmacokinet       Date:  1980 May-Jun       Impact factor: 6.447

Review 10.  Treatment of thromboembolic complications in patients with brain tumors.

Authors:  L K Norris; S A Grossman
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.